Loading
Life sciences · Review
BMC Cancer · November 2, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as potential immunometabolic modulators beyond their established metabolic indications. However, their association with survival outcomes in patients receiving cancer immunotherapy has not been systematically evaluated. We conducted the first meta-analysis to assess the association between GLP-1 RA use and overall survival (OS) in patients with solid tumors receiving immune checkpoint inhibitor (ICI) therapy. PubMed and Embase were systematically searched from inception to July 2026 for cohort studies reporting hazard ratios (HRs) with 95% confidence intervals (CIs) for OS in patients receiving ICIs with or without GLP-1 RA exposure. Pooled HRs were calculated using random-effects models. Exploratory subgroup analyses were performed according to cancer type, and 95% prediction intervals (PIs) were calculated to assess between-study variability. Six retrospective cohort studies were included in the primary meta-analysis, with one study-level OS estimate contributed by each study and a combined reported sample size of 14,833 patients. GLP-1 RA use was associated with improved OS (pooled HR = 0.52, 95% CI: 0.43–0.64; 95% PI: 0.29–0.94), with substantial statistical heterogeneity ( I² = 92.1%). Exploratory cancer-specific analyses showed variation in the magnitude of associations across tumor types, including melanoma (HR = 0.35, 95% CI: 0.26–0.48), urological cancers (HR = 0.35, 95% CI: 0.29–0.43), breast cancer (HR = 0.42, 95% CI: 0.27–0.63), non-small cell lung cancer (HR = 0.58, 95% CI: 0.43–0.78), and digestive system cancers (HR = 0.60, 95% CI: 0.42–0.85). GLP-1 RA use is associated with improved OS among patients with solid tumors receiving ICI therapy. Although the magnitude of the association varied across cancer-specific subgroups, these findings are exploratory and should not be interpreted as evidence of differential effects by cancer type. Given the observational nature of the available evidence, substantial between-study heterogeneity, and potential residual and time-related confounding, these findings should be considered hypothesis-generating and warrant prospective validation.